The main objective of this study is to evaluate the usefulness of tumor MGMT methylation in the prediction of the Objective Response (OR) at 3 months in patients treated with ALKY for a NET, assessed using the RECIST v1.1 criteria by centralized reading carried out by an expert radiologist blinded to the results of the MGMT methylation.